NKGN
NKGen Biotech, Inc.
Set alert
0.06 USD 0.00 0.00%
0.02 Day range 0.02
0.001 52-week range 0.20
- YTD
- +20.00%
- 1 year
- -79.09%
- Open
- 0.02
- Prev close
- 0.06
- Mkt cap
- 7.84M
- Vol
- 200
- Avg vol
- 2.20K
- EPS
- -1.38
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.02
- High
- 0.02
- Forward P/E
- 0.00
- Beta
- 0.52
- Short ratio
- 0.90
- Inst. own
- 12.19%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.3778
- 200-d avg
- 0.986875
- 1y target
- 0.00
Key statistics
- Market cap
- 22.73M
- Enterprise value
- 50.64M
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- -3.42
- Beta
- 0.52
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- 12.75M
- Total cash
- 79.00K
- Total debt
- 28.09M
- Return on equity
- 0.00%
- Shares outstanding
- 35.36M
- Short % of float
- 8.68%
- 50-day average
- 0.3778
- 200-day average
- 0.986875
Analyst view
Consensus: none
Price target (mean) 0.00
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
NKGN Revenue — quarterly 0
NKGN Net income — quarterly 6.60M
NKGN EPS — quarterly 0.23
About NKGen Biotech, Inc.
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. Its lead products include SNK01, an autologous NK cell therapy candidate treatment for neurodegenerative diseases; and SNK02, an allogeneic NK cell therapy, which is in Phase 1 clinical trials for refractory solid tumors. The company has a license agreement with NKMAX. The company was formerly known as NKMAX America, Inc. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkgenbiotech.com
News
- NKGen Biotech to Present on Troculeucel for Neurodegenerative Diseases at 4th Great Bay Cell and Gene Therapy Forum
- NKGen Biotech to Present on Potential of Troculeucel in Neurodegenerative Diseases at Biologics Manufacturing Korea 2026
- NKGen Biotech to Present at the 2026 BIOCHINA Global Forum on Troculeucel’s Potential in Alzheimer’s Disease and Other Neurodegenerative Conditions
- NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment
- NKGen Biotech to Present Troculeucel Mechanism Data in Alzheimer's and Frontotemporal Dementia at the Neuroimmunology Drug Development Summit
- NKGen Biotech Reports Combined Phase 1 Troculeucel Data Demonstrating Dose-Responsive Cognitive Improvements and Biomarker Correlations in Alzheimer's Disease at AD/PD 2026™
- NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026
- Head to Head Contrast: NKGen Biotech (NYSE:NKGN) and SQZ Biotechnologies (NYSE:SQZ)
- Head to Head Comparison: NKGen Biotech (NYSE:NKGN) versus SQZ Biotechnologies (NYSE:SQZ)
- NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D.
Your note
Sign in to keep a note on NKGN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| GRAF JAMES A | Chief Financial Officer | Purchase | Dec 3, 2023 | 2,437,440 |
| PARK SANGWOO | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Dec 12, 2023 | 0 |
| SONG PAUL Y | Chief Executive Officer | Purchase | Dec 6, 2023 | 171,121 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 3.34% | 1,181,872 | 759.71K | Sep 29, 2024 |
| Meteora Capital, LLC | 2.50% | 884,745 | 568.71K | Sep 29, 2024 |
| University of Chicago | 1.56% | 550,000 | 353.54K | Sep 29, 2024 |
| Diametric Capital, Lp | 1.47% | 518,134 | 333.06K | Sep 29, 2024 |
| Vanguard Group Inc | 0.64% | 227,804 | 146.43K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.32% | 112,714 | 72.45K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 0.49% | 174,000 | 111.85K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.19% | 67,693 | 43.51K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.15% | 53,804 | 34.59K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.09% | 32,218 | 20.71K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.05% | 16,106 | 10.35K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.04% | 15,070 | 9.69K | Oct 30, 2024 |